MDR1

Amazon’s Alexa Fund & UI-Investissement Join Investment Round in Sleep Diagnostics Leader Sunrise

Retrieved on: 
Wednesday, November 15, 2023
General Health, FDA, Medical Devices, Other Health, Health, Sleep, Hypertension, Type, Chin, Diaphragm, Fatigue, Jaw, CE, Diagnosis, Sleep-related breathing disorder, MDR1, News, Certification, Pharmaceutical industry, Sunrise, Atlantic Ocean

Sunrise, a pioneer in home sleep diagnostics, has welcomed an additional aggregate investment of $6 million from the Alexa Fund and French healthcare investor UI-Investissement (Majycc Innovation Santé), for a total of $24 million raised this year.

Key Points: 
  • Sunrise, a pioneer in home sleep diagnostics, has welcomed an additional aggregate investment of $6 million from the Alexa Fund and French healthcare investor UI-Investissement (Majycc Innovation Santé), for a total of $24 million raised this year.
  • This new funding enables Sunrise to further expand its reach, making quality sleep diagnostics more accessible and personalized than ever.
  • Joining forces with the Alexa Fund and UI-Investissement, the company is setting a new standard for sleep health.
  • As CEO Laurent Martinot puts it: "This funding round is a vote of confidence, not just in Sunrise, but in the universal need for better sleep health solutions."

Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry

Retrieved on: 
Friday, October 22, 2021
Safety, SORT1, Lung, MDR1, Cancer, Research, Docetaxel, Peptide, Canadian Cancer Society, Mission statement, EDGAR, Survival, Human, NASDAQ, SEDAR, FDA, Forward-looking statement, Agreement Respecting a New Relationship Between the Cree Nation and the Government of Quebec, TSX, Triple-negative breast cancer, Humanitarian use licenses, Senior, TNBC, Christian democracy, Company, Clinical trial, COVID-19, Skin, Health, Neutropenia, GLOBE, Tumor microenvironment, PDC, Doxorubicin, Toxicity, Ovary, Frontiers, Consortium, Fine chemical, Birth control, Pharmaceutical industry

The formation of microvascular channels by deregulated cancer cells leads to aggressive, metastatic and resistant cancer cells and is known as vasculogenic mimicry.

Key Points: 
  • The formation of microvascular channels by deregulated cancer cells leads to aggressive, metastatic and resistant cancer cells and is known as vasculogenic mimicry.
  • VM is believed to be associated with tumor growth, resistance and poor prognosis in many types of aggressive cancers including ovarian and TNBC.
  • Theratechnologies is currently developing a platform of new proprietary peptides for cancer drug development targeting SORT1 receptors called SORT1+ TechnologyTM.
  • TH1902 is currently Theratechnologies lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology.

Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science

Retrieved on: 
Friday, August 13, 2021
Doxorubicin, Triple-negative breast cancer, NASDAQ, Agreement Respecting a New Relationship Between the Cree Nation and the Government of Quebec, MDR1, Clinical trial, Neutropenia, SEDAR, Docetaxel, Canadian Cancer Society, Cancer Science, PDC, Company, TSX, Tumor microenvironment, Senior, Survival, Cancer, Christian democracy, COVID-19, GLOBE, TNBC, Research, Ovary, FDA, Toxicity, Health, Skin, Mission statement, Consortium, Humanitarian use licenses, Lung, SORT1, Safety, Forward-looking statement, EDGAR, Peptide, Pharmaceutical industry, Fine chemical

The article is titled TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.

Key Points: 
  • The article is titled TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.
  • Theratechnologies is currently developing a platform of new proprietary peptides for cancer drug development targeting SORT1 receptors called SORT1+ TechnologyTM.
  • It is highly expressed in cancer cells compared to healthy tissue making it an attractive target for cancer drug development.
  • TH1902 is currently Theratechnologies lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology.